Press release
Irritable Bowel Syndrome Treatment Market to Grow at 8.5% CAGR, Hitting USD 7.4 Billion by 2032 | Persistence Market Research
Irritable Bowel Syndrome Treatment Market
IBS affects approximately 10% to 15% of the global population, with a higher incidence among women and the elderly. The IBS with constipation (IBS-C) segment is expected to dominate, holding 50.2% market share in 2025. Geographically, North America is the leading region, accounting for 38.2% of market share, due to advanced healthcare infrastructure and increasing awareness about IBS management.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/9938
Key Highlights from the Report
Rising prevalence of IBS, particularly in developed nations with stressful urban lifestyles.
Growing patient consultations due to increasing awareness of IBS symptoms and treatment options.
Increase in research and development activities to develop novel therapeutic approaches.
Higher adoption of combination therapies to manage multiple IBS symptoms effectively.
IBS-C is projected to capture 50.2% market share by 2025 due to advancements in constipation treatments.
Linaclotide is expected to dominate the product segment, accounting for 52% market share in 2025.
Market Segmentation
The IBS treatment market is categorized based on product type, treatment approach, and end-users:
By Product Type: The market includes Linaclotide, Rifaximin, Eluxadoline, Alosetron, Lubiprostone, and probiotics. Linaclotide remains the leading product due to its efficacy in managing IBS-C symptoms.
By Treatment Approach: IBS management involves pharmacological treatments, probiotics, dietary modifications, cognitive behavioral therapy, and gut microbiome modulation.
By End-Users: The primary end-users include hospitals, specialty clinics, and retail pharmacies, with retail pharmacies capturing 58% market share due to easy accessibility of over-the-counter IBS medications.
Regional Insights
North America: Market Leader
North America is projected to hold a 38.2% market share in 2025, driven by robust healthcare infrastructure, advanced diagnostic technologies, and higher adoption of targeted therapies. The prevalence of IBS in the region is 11%, with significant investments in gut microbiome research and digital health solutions improving IBS management.
Asia Pacific: Emerging Market
Asia Pacific is anticipated to account for 29.6% of the market share in 2025, growing at a CAGR of 9.8% through 2032. Factors such as increasing awareness, enhanced access to healthcare, and rising demand for innovative treatments are fueling growth. Japan and India are implementing digital health systems for personalized IBS treatment plans.
Market Drivers, Restraints, and Opportunities
Market Drivers
Growing Awareness About IBS Symptoms and Treatment: Rising education and awareness campaigns are encouraging early diagnosis and increasing patient consultations.
Advancements in Gut-Brain Axis Research: New therapies targeting gut microbiome modulation are enhancing treatment effectiveness.
Digital Health Innovations: Mobile apps for IBS symptom tracking and virtual consultations are expanding patient access to expert care.
Market Restraints
Social Stigma Surrounding IBS: Many patients hesitate to seek treatment due to embarrassment, leading to underdiagnosis and reduced market penetration.
Lack of Accurate Prevalence Data: The absence of comprehensive epidemiological studies affects investment in IBS-specific research and drug development.
Market Opportunities
Increasing R&D in Novel Therapies: Investments in microbiome-targeted drugs and combination therapies are shaping the next generation of IBS treatments.
Retail Pharmacies Enhancing Market Reach: The expansion of over-the-counter IBS medications and digital pharmacy solutions is improving treatment accessibility.
Reasons to Buy the Report
✔ Provides a detailed market forecast and CAGR analysis through 2032.
✔ Offers insights into key market drivers, restraints, and opportunities.
✔ Includes comprehensive segmentation analysis by product, treatment approach, and end-users.
✔ Examines regional growth trends, including emerging markets.
✔ Covers competitive landscape, key players, and recent industry developments.
Company Insights and Recent Developments
Key Players in the Market
AbbVie Inc.
Ironwood Pharmaceuticals, Inc.
Takeda Pharmaceuticals
Allergan plc
Bausch Health Companies Inc.
Astellas Pharma Inc.
Nestlé Health Science
Recent Industry Developments
July 2024: Eli Lilly acquired Morphic Holding, a company developing oral integrin therapies for IBS and other chronic diseases.
April 2024: Dr. Reddy's Laboratories launched DailyBloom IBS, India's first integrated care plan for IBS management.
The irritable bowel syndrome treatment market is evolving rapidly, with increasing research in gut microbiome, targeted therapies, and digital health solutions. As awareness and patient access improve, the industry is set for substantial growth in the coming years.
Contact Us:
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com
About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome Treatment Market to Grow at 8.5% CAGR, Hitting USD 7.4 Billion by 2032 | Persistence Market Research here
News-ID: 3932557 • Views: …
More Releases from Persistence Market Research
North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market
The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and…
Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts.
Forged automotive components are critical to…
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the…
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring…
More Releases for IBS
Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs.
👉 Download our latest market insights:…
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR…
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA…
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide.
A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L…
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning.
This also includes consulting services concerning railway systems issues, such as travel…
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011.
The new bulkers, each with a capacity of 176,000 dwt, will be equipped…
